PMID- 32791924
OWN - NLM
STAT- MEDLINE
DCOM- 20211018
LR  - 20211018
IS  - 1532-4206 (Electronic)
IS  - 0743-5800 (Linking)
VI  - 46
IP  - 1
DP  - 2021 Feb
TI  - Silencing of Long Non-coding RNA ENST00000606790.1 Inhibits the Malignant 
      Behaviors of Papillary Thyroid Carcinoma through the PI3K/AKT Pathway.
PG  - 1-9
LID - 10.1080/07435800.2020.1804928 [doi]
AB  - PURPOSE: This study aimed to investigate the role and mechanism of lncRNA 
      ENST00000606790.1 (ENST) in promoting the progression of papillary thyroid 
      carcinoma (PTC). METHODS: The expression of ENST in human PTC and normal 
      para-cancerous thyroid (NPTC) tissues or cell lines was determined by RT-qPCR. 
      Cell growth was determined by CCK8 assay. Cell colony formation was determined by 
      cell colony formation assay. Cell cycle analysis was performed by staining cells 
      with PI (Propidium Iodide). Cell invasion was assessed by transwell assay. 
      Protein expression was examined by western-blot. siRNA was constructed to inhibit 
      the expression of ENST. 740-Y-P was used to activate PI3K. The correlation 
      between ENST expression and clinical outcomes was analyzed. RESULTS: ENST was 
      significantly up-regulated in PTC tissues or PTC cell lines (PTC and IHH4 cell 
      lines), compared to NPTC tissues or normal cell lines, respectively. High 
      expression of ENST was strongly correlated to lymph node metastasis and tumor 
      size at diagnosis. Silencing of ENST significantly inhibited cell growth and 
      colony formation, arrested the cell cycle at G2/M phase, upregulated the 
      expression of CHK1, downregulated the expression of CDC25C, and inhibited cell 
      invasion. Silencing of ENST significantly down-regulated the expression of PI3K, 
      p-PI3K, AKT, and p-AKT in IHH4 cells. Furthermore, treatment with the PI3K 
      activator  740-Y-P partially abolished the effect of silencing of ENST on PTC 
      cells. CONCLUSIONS: Overall, our results demonstrated that ENST can promote PTC 
      progression by activating the PI3K/AKT signaling pathway, suggesting that ENST 
      can serve as a potential biomarker and new therapeutic target for patients with 
      PTC.
FAU - Zuo, Zhihua
AU  - Zuo Z
AD  - Department of Endocrinology, The Second Affiliated Hospital of Nanjing Medical 
      University , Nanjing, China.
AD  - Department of Endocrinology, The Affiliated Jiangning Hospital of Nanjing Medical 
      University , Nanjing, China.
FAU - Liu, Ling
AU  - Liu L
AD  - Department of Endocrinology, The Second Affiliated Hospital of Nanjing Medical 
      University , Nanjing, China.
FAU - Song, Bin
AU  - Song B
AD  - Department of Endocrinology, The Second Affiliated Hospital of Nanjing Medical 
      University , Nanjing, China.
FAU - Tan, Juan
AU  - Tan J
AD  - Department of Gerontology, Huai'an First People's Hospital, Nanjing Medical 
      University , Huai'an, China.
FAU - Ding, Dafa
AU  - Ding D
AD  - Department of Endocrinology, The Second Affiliated Hospital of Nanjing Medical 
      University , Nanjing, China.
FAU - Lu, Yibing
AU  - Lu Y
AD  - Department of Endocrinology, The Second Affiliated Hospital of Nanjing Medical 
      University , Nanjing, China.
LA  - eng
PT  - Journal Article
DEP - 20200813
PL  - England
TA  - Endocr Res
JT  - Endocrine research
JID - 8408548
RN  - 0 (Biomarkers)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (RNA, Small Interfering)
RN  - EC 2.7.11.1 (Oncogene Protein v-akt)
SB  - IM
MH  - Biomarkers/metabolism
MH  - Cell Line, Tumor
MH  - Gene Expression Regulation, Neoplastic/*genetics
MH  - Humans
MH  - Microarray Analysis
MH  - Oncogene Protein v-akt/*metabolism
MH  - Phosphatidylinositol 3-Kinases/*metabolism
MH  - *RNA Interference
MH  - RNA, Long Noncoding/*metabolism
MH  - RNA, Small Interfering/*metabolism
MH  - Signal Transduction/*genetics
MH  - Thyroid Cancer, Papillary/*metabolism
MH  - Thyroid Neoplasms/*metabolism
OTO - NOTNLM
OT  - Long non-coding RNA
OT  - Pi3k/AKT pathway
OT  - microarray analysis
OT  - siRNA
OT  - thyroid carcinoma
EDAT- 2020/08/15 06:00
MHDA- 2021/10/21 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
PHST- 2020/08/15 06:00 [entrez]
AID - 10.1080/07435800.2020.1804928 [doi]
PST - ppublish
SO  - Endocr Res. 2021 Feb;46(1):1-9. doi: 10.1080/07435800.2020.1804928. Epub 2020 Aug 
      13.